Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756040 | 1.00 | ALOX15 (0.38) | ALOX15CYP1B1ALDH1A1LMNAESR1 | |
| SCHEMBL10886649 | 1.00 | ALOX15 (0.38) | ALOX15CYP1B1ALDH1A1LMNAESR1 | |
| SCHEMBL11103446 | 0.81 | LMNA (0.42) | ALOX15CYP1B1ALDH1A1LMNA | |
| SCHEMBL9129884 | 0.81 | — | — | |
| SCHEMBL513994 | 0.81 | — | — | |
| SCHEMBL19521458 | 0.80 | HSD17B10 (0.36) | ESR1CYP3A4CYP2C9ESR2 | |
| SCHEMBL18084349 | 0.78 | LMNA (0.52) | ALOX15CYP1B1ALDH1A1LMNATHRA | |
| SCHEMBL20393419 | 0.78 | LMNA (0.52) | ALOX15CYP1B1ALDH1A1LMNATHRA | |
| SCHEMBL16266541 | 0.78 | HTT (0.38) | ALOX15CYP1B1ALDH1A1LMNACYP2C9 | |
| SCHEMBL8950756 | 0.75 | ESR1 (0.33) | ESR1CYP3A4CYP2C9ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4298762-A | OPPENAUER OXIDATION USING FURFURAL AS HYDROGEN ACCEPTOR | SCM CORPORATION (US) | 1981-11-03 | — | — | US | claimed |
| US-3993604-A | ORGANOLEPTIC, PERFUMES, FLAVORS | FIRMENICH S.A. (CH) | 1976-11-23 | — | — | US | claimed |
| US-20260117236-A1 | METHODS AND COMPOSITIONS FOR MODULATING TRICHOME DENSITY AND FLAVOR MOLECULE SECRETION | ALTRIA CLIENT SERVICES LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| US-12303488-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-05-20 | — | — | US | disclosed |
| CN-118541213-A | Polydisulfide core-shell microcapsules | 弗门尼舍有限公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-4417252-A2 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | Yuzu LV LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240216457-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| EP-2036876-A1 | ALCOHOL COMPOUNDS | Kao Corporation (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20040092423-A1 | Composition for reducing fabric wrinkles and method for using the same | DIAL CORPORATION, THE | 2004-05-13 | — | — | US | disclosed |
| US-20040087651-A1 | Monoterpene as a chemopreventive agent for regression of mammalian nervous system cell tumors, use of monoterpene for causing regression and inhibition of nervous system cell tumors, and method for administration of monoterpene perillyl alcohol | PEREIRA DA FONSECA CLOVIS ORLA (BR) | 2004-05-06 | — | — | US | disclosed |
| US-20030199402-A1 | Composition for reducing malodors and method for using the same | DIAL CORPORATION, THE | 2003-10-23 | — | — | US | disclosed |
| US-5759528-A | AMINE OXIDE SURFACTANT AND CYCLOHEXANE, CYCLOHEXENE OR CYCLOHEXANONE DERIVATIVE | INSTITUTE FOR ADVANCED SKIN RESEARCH, INC. (JP) | 1998-06-02 | — | — | US | disclosed |
| EP-0745389-A1 | COMPOSITION FOR TOPICAL APPLICATION | INSTITUTE FOR ADVANCED SKIN RESEARCH INC. (JP) | 1996-12-04 | — | — | EP | disclosed |
| US-4719105-A | Method, compositions and compounds useful in room fresheners employing cyclohexyl alcohol and ester derivatives | BUSH BOAKE ALLEN, INC. (GB) | 1988-01-12 | — | — | US | disclosed |
| US-4622221-A | Method, compositions and compounds, useful in room fresheners employing cyclohexyl alcohol and ester derivatives | BUSH BOAKE ALLEN INC. (US) | 1986-11-11 | — | — | US | disclosed |
| US-3993604-A | ORGANOLEPTIC, PERFUMES, FLAVORS | FIRMENICH S.A. (CH) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | ALOX15 11/4885CYP1B1 138/4885ALDH1A1 1420/4885 |
| US-20260117236-A1 | METHODS AND COMPOSITIONS FOR MODULATING TRICHOME DENSITY AND FLAVOR MOLECULE SECRETION | TAS2R50, TAS2R30, TAS2R31 | ALOX15 1309/4885CYP1B1 503/4885ALDH1A1 3954/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | ALOX15 121/4885CYP1B1 2141/4885ALDH1A1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.